secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021834
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q3 2022: Cash $519M, $15M revenue; FDA positive feedback on FT516 RMAT; pipeline progress
--------------------------------------------------------------------------------

- Cash and investments $519.1M; Q3 revenue $15.0M from Janssen/ONO collaborations; R&D expense $79.8M.
- Positive FDA feedback under FT516 RMAT for clonal master iPSC bank and potential registrational study design; CMC meeting set for December.
- Enrollment ongoing for FT596+R three-dose escalation at 1.8B cells/dose for R/R BCL; activating community sites for FT596+R-CHOP in newly-diagnosed aggressive BCL.
- Janssen exercised option for second iPSC-derived CAR NK product targeting undisclosed hematologic malignancy antigen; FT555 (GPRC5D) IND candidate for MM to be presented at ASH.
- 14 abstracts selected for ASH and 12 for SITC, including interim Phase 1 data for FT576 (MM), FT819 (BCL), FT536/FT538 (solid tumors).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/0000950170-22-021834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/fate-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer